Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MNOV vs ENTX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ENTX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 4–5 Matrix Metrics)

ENTX Overall Winner 6-Pillar Tally: MNOV 2 – 3 ENTX (1 Tie) Matrix Metrics: MNOV 5 – 4 ENTX

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Medicinova, Inc. (MNOV) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1232.2% operating margin) and revenue trajectory (-100.0% vs. +12.4% YoY).
  • Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MNOV vs ENTX
MNOV NASDAQ
Medicinova, Inc.
Pharmaceutical Preparations
$1.31
+3.15% 1D
Market Cap $65.1M
TTM Revenue $935,717
Forward P/E 8.5x
Beta / 30D Vol 0.59β · 38% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 47.0 Fund 46.0 Flow 63.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.5%), weak momentum, RSI 36
RSI-14: 36.4 · SMA20: $1.40 · SMA50: $1.74
ENTX NASDAQ Head-to-Head Winner
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.31
+0.76% 1D
Market Cap $571.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.92β · 53% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 52.0 Fund 49.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.4% over 20 days), RSI 61
RSI-14: 61.2 · SMA20: $3.13 · SMA50: $2.93

6-Pillar Scorecard Institutional Category Breakdown (MNOV 2 – 3 ENTX)

Columns: Metric · MNOV · ENTX
1. Valuation Multiples MNOV
Forward P/E 8.5x N/M
Trailing P/E 8.5x N/M
PEG Ratio N/M N/M
EV / Revenue 42.5x N/M
2. Growth & Scale MNOV
Revenue Growth (YoY) +12.4% -100.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $935,717 N/A
Market Cap $65.1M $571.2M
3. Profitability & Quality ENTX
Gross Margin 42.2% N/A
Operating Margin -1232.2% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -24.8% -20.3%
4. Balance Sheet & Cash Flow ENTX
Cash Generation (TTM) -$9.1M -$16M
Cash Flow Margin N/A N/A
Net Cash / Leverage $25M Net Cash $265M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ENTX
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 140.1% (50th %ile) 116.0% (33rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MNOV (5) vs ENTX (4)
Institutional Metric MNOV ENTX Criterion Row Edge
Market Capitalization
Scale
$65.1M $571.2M Larger Scale ENTX
Trailing P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Forward P/E Ratio
Valuation
8.5x N/M Lower Multiple MNOV
Revenue Growth (YoY)
Growth
+12.4% -100.0% Higher Growth MNOV
Operating Margin (TTM)
Profitability
-1232.2% 0.0% Higher Margin ENTX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-24.8% -20.3% Higher ROE ENTX
52-Week Range Position
Momentum
3% ($1–$4) 73% ($1–$4) Stronger Trend ENTX
Beta / 30D Volatility
Risk Regime
0.59β · 38% Vol 0.92β · 53% Vol Lower Realized Risk MNOV
Unified Institutional Score
Composite Signal
50.2 / 100 (HOLD) 47.5 / 100 (HOLD) Higher Composite MNOV
Trailing 12M Revenue (USD)
Operating Scale
$935,717 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
42.2% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 42.5x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$9.1M ($25M Net Cash) -$16M ($265M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENTX +16.53 pp
MNOV: -7.09% · ENTX: +9.44%
3M Horizon ENTX +11.02 pp
MNOV: -14.38% · ENTX: -3.36%
6M Horizon ENTX +172.96 pp
MNOV: -6.43% · ENTX: +166.53%
1Y Horizon ENTX +33.11 pp
MNOV: -8.39% · ENTX: +24.72%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MNOV Revenue ENTX Revenue MNOV Op. Margin ENTX Op. Margin Margin Leader
FY2012 $0M N/A -1363.8% N/A MNOV
FY2020 N/A $0M N/A -3059.7% ENTX
FY2021 $0M $0M -253.0% -2139.6% MNOV
FY2022 N/A $0M N/A -9714.2% ENTX
FY2023 $0M N/A -990.0% N/A MNOV
FY2024 N/A $0M N/A -5295.6% ENTX
FY2025 $0M $0M -3242.5% -27450.0% MNOV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 140.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact MNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENTX CONSOLIDATION
83d in phase · OBV NEUTRAL
Current IV 116.0%
IV Percentile 33rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ENTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MNOV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $65.1M market capitalization and -1232.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $571.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MNOV vs ENTX Key Questions & Quantitative Answers

As of Nov 20, 2026, Entera Bio Ltd. (ENTX) is the stronger overall head-to-head candidate over Medicinova, Inc. (MNOV) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). MNOV carries a Unified Composite Score of 50.2/100 (HOLD) at $1.31 (8.5x Forward P/E, -1232.2% operating margin), whereas ENTX carries 47.5/100 (HOLD) at $3.31 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MNOV currently prints a higher short-term Unified Composite Score (50.2/100 HOLD vs. ENTX 47.5/100 HOLD), ENTX captures the overall institutional head-to-head verdict (4–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -1232.2% operating margin) and revenue trajectory (-100.0% vs. +12.4% YoY). Technical & Structure Timing Caution: MNOV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.4); meanwhile ENTX trades in a Markup technical trend (CONSOLIDATION options phase, RSI 61.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MNOV leads the Growth & Scale pillar: MNOV posts +12.4% YoY revenue growth and +0.0% YoY earnings growth on $935,717 TTM revenue (42.2% gross margin, -1232.2% operating margin), compared with ENTX at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2012 to FY2025), MNOV cumulative revenue shifted N/A while ENTX shifted N/A. In operating R&D and SG&A reinvestment, MNOV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENTX.

MNOV screens cheaper on headline valuation multiples. MNOV trades at 8.5x Forward P/E, 8.5x Trailing P/E, N/M PEG, and 42.5x EV/Revenue (unreported FCF margin), whereas ENTX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MNOV (-24.8% ROE) versus ENTX (-20.3% ROE) capital efficiency.

In options market volatility and institutional positioning, MNOV carries 140.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 38% Vol realized risk). By comparison, ENTX carries 116.0% implied volatility (33rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.92β · 53% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.